Le groupe pharmaceutique français Sanofi veut se séparer de son pôle médicaments grand public parmi lesquels le Doliprane. Et ce projet du PDG avance désormais à grande vitesse. Les explications de Pierre Kupferman.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
